Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.056
Sell
RSI(14)
37.392
Neutral
STOCH(KDJ)(9,3,3)
11.798
Oversold
ATR(14)
0.109
Low Volatility
CCI(14)
-86.446
Neutral
Williams %R
94.490
Oversold
TRIX(12,20)
-0.526
Sell
StochRSI(14)
0.000
Sell
Search
ProKidney Corp
PROKAdd to Watchlist
1.512USD
-0.008-0.54%
Close 07-23 16:00（ET）Quotes delayed by 15 min
214.38MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.54%
5 Days
-6.10%
1 Month
-16.01%
6 Months
-30.33%
Year to Date
-32.51%
1 Year
-53.05%
Key Figures
1.510Open
1.539High
25.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
1.520Prev. Close
1.480Low
38.00Turnover
LossP/E Static
-0.21P/B
0.00%Div Yield TTM
-44.73%ROA
7.13052wk High
-0.00Volume Ratio
-61.19MNet Profit
141.81MShares
-0.5265EPS TTM
1.71Beta
--ROE
0.54052wk Low
3.86%Amplitude
100.00%Gross Margin
214.38MMarket Cap
-2.64Reward/Risk
5.35%Risk Rate
TradingKey Stock Score of ProKidney Corp
Currency: USD Updated: 2026-07-23Key Insights
ProKidney Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 123 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.30.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProKidney Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
ProKidney Corp Highlights
StrengthsRisks
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 893.00K.
Overvalued
The company’s latest PE is -2.89, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 50.49M shares, increasing 8.56% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 1.31K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.33.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
7.300
Target Price
+357.68%
Upside Space
ProKidney Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
7.300
Target Price
+357.68%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
ProKidney Corp
PROK
9
Beigene Ltd
ONC
28
argenx SE
ARGX
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.565
Sell
MA10
1.595
Sell
MA20
1.746
Sell
MA50
1.742
Sell
MA100
1.870
Sell
MA200
2.153
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ProKidney Corp Info
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Ticker SymbolPROK
CompanyProKidney Corp
CEOCulleton (Bruce)
Websitehttps://prokidney.com/
Shareholders
Related Instruments
-0.24%
0.00%
0.00%
0.00%
0.00%
-1.09%
0.00%
+0.77%
0.00%
-1.20%
+0.02%
0.00%
0.00%
-1.66%
0.00%
0.00%
0.00%
+0.42%
+1.31%
0.00%Popular Instruments
FAQs
What is the current price of ProKidney Corp (PROK)?
The current price of ProKidney Corp (PROK) is 1.53.
What is the symbol of ProKidney Corp?
The ticker symbol of ProKidney Corp is PROK.
What is the 52-week high of ProKidney Corp?
The 52-week high of ProKidney Corp is 7.13.
What is the 52-week low of ProKidney Corp?
The 52-week low of ProKidney Corp is 0.54.
What is the market capitalization of ProKidney Corp?
The market capitalization of ProKidney Corp is 216.97M.
Is ProKidney Corp (PROK) currently rated as Buy, Hold, or Sell?
According to analysts, ProKidney Corp (PROK) has an overall rating of Buy, with a price target of 7.30.
What is the Earnings Per Share (EPS TTM) of ProKidney Corp (PROK)?
The Earnings Per Share (EPS TTM) of ProKidney Corp (PROK) is -0.52.